TITLE

US stem cell climate improves, raising concerns elsewhere

AUTHOR(S)
Siva, Nayanah
PUB. DATE
March 2009
SOURCE
Nature Medicine;Mar2009, Vol. 15 Issue 3, p224
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that the U.S. Food and Drug Administration (FDA) approved the biotech company Geron Corp. to perform a stem cell trial for people with acute spinal injury. It states that the trial is designed to determine the safety of the stem cell approach to 8-10 paralyzed subjects. Geron's researchers will inject glial cells derived from the human embryonic stem cells directly into the spinal lesion sites.
ACCESSION #
36818286

 

Related Articles

  • Animal Spine Cysts Delay Trial with Geron's ESC for Injuries. Boggs, Jennifer // BioWorld Today;8/28/2009, Vol. 20 Issue 166, p1 

    The article reports that trial of the human embryonic stem cell (hESC)-based therapy GRNOPCI has been delayed by Geron Corp. because of the lack of cysts in animal models. The company has yet to decide when to start the first phase of the trial with the hESC-derived oligodendrocyte therapy. On...

  • FDA okays first embryonic stem-cell trial.  // Medical Device Daily;1/26/2009, Vol. 13 Issue 15, p2 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) for biotechnology company Geron to evaluate the use of embryonic stem cells for spinal cord injuries in as many as 10 patients. The company's proposed study will address a one-year therapy regime for spinal-cord...

  • Geron Soars as First ESC Trial Clears FDA Hurdle. Boggs, Jennifer // BioWorld Today;1/26/2009, Vol. 20 Issue 15, p1 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) for the Phase I trial of GRNOPCI, human embryonic stem cells (hESC)-derived oligodendrocytes of Geron Corp. in patients with spinal cord injury. Thomas Okarma, president and chief executive officer of Geron,...

  • Stem Cell Study Patients May Need Long-Term Monitoring. Young, Donna // BioWorld Today;4/11/2008, Vol. 19 Issue 71, p1 

    The article focuses on the need for patients involved in studies of cellular therapies derived from human embryonic stem cells (hESCs) to be monitored throughout their lifetime for tumors or other abnormalities, according to the U.S. Food and Drug Administration's Cellular, Tissue and Gene...

  • FDA ROUNDUP.  // MondayMorning;1/26/2009, Vol. 17 Issue 3, p1 

    The article reports on the approval given to Geron Corp. of Menlo Park, California by the U.S. Food & Drug Administration to begin the first human test of embryonic stem cells on humans. According to the article, the stem-cell test will attempt to restore movement to paralyze people by injecting...

  • Second hESC Trial Clears FDA; ACT Set to Start Phase I/II Study. Young, Donna // BioWorld Today;11/23/2010, Vol. 21 Issue 227, p1 

    The article reports that shares of Advanced Cell Technology Inc. (ACT) rose by as much as 70 percent following the decision of the Food and Drug Administration (FDA) in the U.S. removed the clinical hold on the human embryonic stem cell (hESC) trial in Stargardt's macular dystrophy of the...

  • RESEARCH & TECHNOLOGY.  // MondayMorning;11/23/2009, Vol. 17 Issue 45, p4 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) to use the investigational new drug application of human embryonic stem cells introduced by Advanced Cell Technology Inc. (ACT). The company and FDA have conducted a thorough review to determine its side effects...

  • Seven days: 7?13 January 2011.  // Nature;1/13/2011, Vol. 469 Issue 7329, p136 

    The article offers world news briefs. In the U.S., the Food and Drug Administration (FDA) approved the use of human embryonic stem cells to treat Stargardt's disease. In Venezuela, President Hugo Chávez vetoed a law that placed the budget and elections of universities under local citizens'...

  • The promise and peril of stem cell research. Couzin, Jennifer // U.S. News & World Report;05/31/99, Vol. 126 Issue 21, p68 

    Describes the benefits and drawbacks of stem cell research. Work of Evan Snyder at Boston Children's Hospital in Massachusetts; Moral dilemmas associated with the cells; Government funding for the research; Human stem cells as opposed to animals'; Debate over stem cells similar to that over...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics